Alecensa (alectinib hydrochloride) NDC 50242-130

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-130Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0130Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50242-130-01	50242013001	1 BOTTLE, PLASTIC in 1 CARTON (50242-130-01) / 240 CAPSULE in 1 BOTTLE, PLASTICMarketed from Dec 11, 2015
50242-130-86	50242013086	1 BOTTLE, PLASTIC in 1 CARTON (50242-130-86) / 240 CAPSULE in 1 BOTTLE, PLASTICMarketed from Oct 10, 2017 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alecensa
Generic name (nonproprietary): alectinib hydrochloride
Active ingredients: Alectinib hydrochloride — 150 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Genentech, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208434
Marketing start: Dec 11, 2015
Listing expires: Dec 31, 2027
Other FDA classes: Kinase Inhibitors (Mechanism)
Identifiers: Product ID 50242-130_3159555e-f227-4168-9e96-96f5b705fad2SPL ID 3159555e-f227-4168-9e96-96f5b705fad2SPL set ID 42c49deb-713b-427a-9670-08af08adcffbRxCUI 1727479, 1727485UNII P9YY73LO6J
Pharmacologic class: Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450242013001 followed by a unit qualifier and the quantity

Package 50242-0130-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 21, 2026.

Indications (excerpt from the label)

ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by an FDA-approved test. ( 1.1 ) treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. ( 1.2 ) 1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC) ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test [see…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)